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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 4 9 – 4 5 2 451indeed to any process for making valid generalizations based on
evidence.
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1246–1253.Response about Rank ReversalTo the Editor—We thank van Valkenhoef and Ades [1] for their analysis [3–6]. This observation does not lessen the importance of
comments on our article about rank reversal [2] and for raising
several important issues. Their letter reminds readers about the
growing importance of meta-analyses in clinical decision making,
and its potential value to synthesize findings across multiple studies.
While our comments in this response focus on issues related to
meta-analysis, it is important to note that rank reversal is a general
phenomenon whose importance extends beyond meta-analysis.
Van Valkenhoef and Ades’ main point is that indirect compar-
ison meta-analyses assume exchangeability, meaning that all
trials measure the same underlying relative effects on the same
measure (typically risk difference, risk ratio, or odds ratio). Their
conclusion is that the choice of measure (or scale) is derived from
nature and is not a matter of choice. A statistical model
estimated by using one measure is inherently incompatible with
models estimated on another.
We agree with the technical point that the assumption of
exchangeability means that the treatment effect can be homo-
geneous on at most one measure (risk difference, risk ratio, or
odds ratio). As they point out, others have made this observation
as the literature has struggled to understand the importance of
heterogeneous treatment effects in indirect comparison meta-accounting for rank reversal in practice.
Because researchers never know which measure, if any, is
constant in nature, one could in principle use statistical tests to
compare measures. Cochran’s Q statistic [7] and DerSimonian and
Laird’s [8] Q statistic are used to measure the existence of hetero-
geneity. Higgins and Thompson’s I2 statistic measures the degree of
heterogeneity [9]. Conceivably, these tests can identify the condi-
tions under which the assumption of exchangeability is maintained.
There are several reasons these statistical tests are challen-
ging in practice. First, while exploring heterogeneity among
studies included in a meta-analysis has become common [8],
the comparison of heterogeneity between various measures is
not. Unfortunately, making decisions based on these statistical
tests is difficult, in part because the literature does not identify
what acceptable thresholds should be. Most meta-analyses do
not compare across measures. Even when tests of heterogeneity
indicate an appropriate measure, making decisions based solely
on these statistical tests without considering empirical evidence
is not advised [10]. So, while theory suggests that a single measure
will be revealed, in practice this information is not easily deter-
mined and should rely on context as well as statistics.elationships to disclose.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 4 9 – 4 5 2452Second, there are additional statistical challenges to these
tests. DerSimonian and Laird’s [8] Q statistic is specific to random
effects models, while Cochran’s Q statistic [7] is not presented in
the context of covariates: their original derivation is only for
models that do not control for confounding. This is presumably
because the authors are well aware that one cannot directly
compare magnitudes of odds ratios from separate analyses, a
point only recently highlighted in the applied literature [11–13]. In
addition, because of differences in the weighting of trials when
calculating Cochran’s Q for different summary statistics, these
comparisons may not be particularly meaningful and may be
misleading [10].
Third, in practice estimating a model with a rich specification
of covariates can provide a good approximation to other models.
We showed this in another article in which multivariate logistic
regression could recover the adjusted risk ratio even when the
data generating process is an odds ratio [14]. DerSimonian and
Laird [8] also argue that although choosing the wrong measure
could imply heterogeneity in treatment effects, in practice this
would not tend to happen unless the rate for the control group
varied widely or was close to either zero or one.
Fourth, our preferred approach to choosing a measure is to
begin with the policy or research question. Even if this approach
requires tolerating reduced precision because of heterogeneity,
we hold with Tukey [15], ‘‘Far better an approximate answer to
the right question, which is often vague, than an exact answer to
the wrong question, which can always be made precise.’’ We
consider the statistics to serve the substance and not vice versa.
We thank Valkenhoef and Ades for their careful read of our
article, and for drawing attention to important issues about
conducting meta-analyses. Their letter is a great reminder that
assumptions matter, that some statistical models are theoreti-
cally incompatible with seemingly similar models, and that
getting the right statistical model is extremely important. We
hope that this exchange will generate better understanding of the
strengths and weaknesses of different approaches to indirect
comparison meta-analyses.Edward C. Norton, PhD
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